Nobili Valerio, Socha Piotr
Hepatometabolic Diseases Unit and Liver Research Unit Bambino Gesu Children Hospital, Rome.
Pediatric Department University La Sapienza-Rome, Italy.
J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):188-192. doi: 10.1097/MPG.0000000000001823.
Nonalcoholic fatty liver disease (NAFLD), an increasingly prevalent paediatric disorder, is diagnosed and managed not only by both pediatric gastroenterologists/hepatologists but also frequently by the general pediatrician. This article updates recent advances in diagnostic and therapeutic approach, which may be applied to everyday practice. Diagnosis of NAFLD takes into account the risk factor profile and is a diagnosis of exclusion. Techniques such as transient elastography and specific biomarkers aimed at improving diagnosis and monitoring of NAFLD need further validation in the pediatric population. Defining the risk to develop cirrhosis seems to be of primary importance already in childhood and a combination of genetic, clinical, and environmental factors can help in monitoring and making decisions on therapy. Weight reduction therapy should be the aim of treatment approach, but the compliance is poor and pharmacological treatment would be helpful; docosahexaenoic acid, some probiotics, and vitamin E are to be considered, but evidence is not sufficient to recommend widespread use.
非酒精性脂肪性肝病(NAFLD)是一种在儿科中日益普遍的疾病,不仅由儿科胃肠病学家/肝病学家进行诊断和管理,普通儿科医生也经常参与其中。本文更新了诊断和治疗方法的最新进展,这些进展可能应用于日常临床实践。NAFLD的诊断需考虑危险因素概况,且是一种排除性诊断。诸如瞬时弹性成像和旨在改善NAFLD诊断与监测的特定生物标志物等技术,在儿科人群中还需进一步验证。确定发生肝硬化的风险在儿童期似乎就至关重要,遗传、临床和环境因素的综合考量有助于监测和制定治疗决策。减轻体重疗法应是治疗方法的目标,但依从性较差,药物治疗可能会有所帮助;二十二碳六烯酸、某些益生菌和维生素E可予以考虑,但证据不足以推荐广泛使用。